Love it or leave it: GLP-1 edition 👀 • Semaglutide? Leave it. Around 17% report side effects. Helpful short term, not a forever solution • Tirzepatide? Netflix and chill. Works well for a season, but not something to commit to long term • Retatrutide (the newer triple-action)? Love it. Hits three pathways and may offer bigger benefits with fewer side effects • New oral GLP-1s? Leave it. Roughly $1,000 a month, mainly for maintenance, and may spike cortisol • Injectables for 12 months with no br